Of four treatment response measures recorded at 6 months of mepolizumab treatment, an Asthma Control Questionnaire score was ...

During the 43rd J.P. Morgan Annual Healthcare Conference last month, Areteia Therapeutics took centre stage, presenting a ...

Head of “Living With”, Mariel Metcalfe, discusses the nature of severe asthma and severe eosinophilic asthma, and presents some key findings from recent patient research conducted in Europe ...

Initially developed for atopic dermatitis, Enveda's lead asset ENV-294 is now showing promise in treating asthma.

Qin Rao, MD, is a board-certified physician based in New York City. He currently works as a gastroenterologist and hepatologist at Manhattan Gastroenterology. Eosinophilic esophagitis (EoE) is a ...

Specifically, Dupixent is approved to treat moderate to severe asthma that is either: dependent on treatment with an oral corticosteroid, or eosinophilic (caused by an increase in eosinophils ...

mail.newcastle.edu.au Airway inflammation with eosinophils is now reported to occur not only in asthma but in other airway diseases such as cough variant asthma, chronic cough, atopic cough, episodic ...

Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...

The SARS-CoV-2 pandemic interrupted much respiratory research. Respiratory clinical academics joined colleagues in providing clinical care, and global research efforts were directed to finding new ...

GSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor ...

The Odessa American is the leading source of local news, information, entertainment and sports for the Permian Basin.